Log In
BCIQ
Print this Print this
 

CAR-NKG2D (NKG2D CAR T cells) (CM-CS1, NKR-2)

  Manage Alerts
Collapse Summary General Information
Company Celyad S.A.
DescriptionAutologous chimeric antigen receptor (CAR) T cells targeting killer cell lectin-like receptor subfamily K member 1 (NKG2D; KLRK1; CD314)
Molecular Target Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$489.0M

$18.3M

$466.7M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today